NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-181197 | Pharmaceuticals
Historical data: 2017 - 2023
Forecast period: 2025 - 2031
Quantitative units: Revenue in USD million and CAGR from 2025 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Novel Oral AntiCoagulants (NOAC) Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET
7.1 GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)
8.1 GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
8.2 GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
9.1 GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
9.2 GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
10.1 GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)
10.2 GLOBAL NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)
11.1 NORTH AMERICA NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
11.2 NORTH AMERICA NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
11.3 NORTH AMERICA NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
11.4 NORTH AMERICA NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
11.5 NORTH AMERICA NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
11.6 NORTH AMERICA NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
12.1 EUROPE NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
12.2 EUROPE NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
12.3 EUROPE NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
12.4 EUROPE NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
12.5 EUROPE NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
12.6 EUROPE NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
13.1 ASIA PACIFIC NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
13.2 ASIA PACIFIC NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
13.3 ASIA PACIFIC NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
13.4 ASIA PACIFIC NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
13.5 ASIA PACIFIC NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
13.6 ASIA PACIFIC NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
14.1 LATIN AMERICA NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>
14.2 LATIN AMERICA NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
14.3 LATIN AMERICA NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
14.4 LATIN AMERICA NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
14.5 LATIN AMERICA NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
14.6 LATIN AMERICA NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA NOVEL ORAL ANTICOAGULANTS (NOAC) MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>
16.1 Johnson & Johnson
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Bristol-Myers Squibb
16.3 Boehringer Ingelheim
16.4 Sanofi
16.5 Daiichi Sankyo
16.6 Armatheon
16.7 Aspen
16.8 AstraZeneca
16.9 Bayer
16.10 Cellceutix
16.11 Cosmo Pharmaceuticals
16.12 CSL Behring
16.13 Eisai
16.14 GSK
16.15 Marathon Pharmaceuticals
16.16 Ockham Bio
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
Market by Type :Direct Thrombin Inhibitors
Direct Factor Xa Inhibitors
Market by Application :
Deep Vein Thrombosis (DVT)
Pulmonary Embolism
Acute Coronary Syndrome
Hemodialysis
Others
Companies
Johnson & Johnson
Bristol-Myers Squibb
Boehringer Ingelheim
Sanofi
Daiichi Sankyo
Armatheon
Aspen
AstraZeneca
Bayer
Cellceutix
Cosmo Pharmaceuticals
CSL Behring
Eisai
GSK
Marathon Pharmaceuticals
Ockham Bio
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.